Author Archives: Anne-Marie Rohrstock

Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures

Sebastian Palmqvist, Pontus Tideman, Nicholas Cullen, Henrik Zetterberg, Kaj Blennow, the Alzheimer’s Disease Neuroimaging Initiative, Jeffery L. Dage, Erik Stomrud, Shorena Janelidze, Niklas Mattsson-Carlgren & Oskar Hansson Nature Medicine volume 27, pages 1034–1042 (2021) Abstract A combination of plasma phospho-tau (P-tau) and other accessible biomarkers might provide accurate prediction about the risk of developing Alzheimer’s […]

Early stages of tau pathology and its associations with functional connectivity, atrophy and memory.

Berron D, Vogel JW, Insel PS, Pereira JB, Xie L, Wisse LEM, Yushkevich PA, Palmqvist S, Mattsson-Carlgren N, Stomrud E, Smith R, Strandberg O, Hansson O.Brain. 2021 Mar 16:awab114. doi: 10.1093/brain/awab114. Online ahead of print.PMID: 33725124 Abstract In Alzheimer’s disease, postmortem studies have shown that the first cortical site where neurofibrillary tangles appear is the transentorhinal […]

Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease.

Gertje EC, van Westen D, Panizo C, Mattsson-Carlgren N, Hansson O. Neurology. 2021 Jan 12;96(2):e193-e202 Abstract Objective: To investigate the relationship between enlarged perivascular spaces (EPVS) and measures of Alzheimer disease (AD), small vessel disease (SVD), cognition, vascular risk factors, and neuroinflammation, we tested associations between EPVS and different relevant neuroimaging, biochemical, and cognitive variables in […]

Pre-analytical protocol for measuring Alzheimer’s disease biomarkers in fresh CSF.

Hansson O, Rutz S, Zetterberg H, Bauer E, Hähl T, Manuilova E, Mert MC, Wahl S, Blennow K, Stomrud E. Alzheimers Dement (Amst). 2020 Dec 18;12(1):e12137 Abstract Introduction: We aimed to establish a standardized, routine-use pre-analytical protocol for measuring Alzheimer’s disease (AD) biomarkers in cerebrospinal fluid (CSF). Methods: The effect of pre-analytical factors (sample collection/handling/storage/transportation) on biomarker […]

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies.

Mattsson-Carlgren N, Palmqvist S, Blennow K, Hansson O. Nat Commun. 2020 Dec 7;11(1):6252 Abstract Biomarkers have revolutionized scientific research on neurodegenerative diseases, in particular Alzheimer’s disease, transformed drug trial design, and are also increasingly improving patient management in clinical practice. A few key cerebrospinal fluid biomarkers have been robustly associated with neurodegenerative diseases. Several novel […]

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease.

Mattsson-Carlgren N, Janelidze S, Palmqvist S, Cullen N, Svenningsson AL, Strandberg O, Mengel D, Walsh DM, Stomrud E, Dage JL, Hansson O. Brain. 2020 Dec 5;143(11):3234-3241 Abstract Plasma levels of tau phosphorylated at threonine-217 (p-tau217) is a candidate tool to monitor Alzheimer’s disease. We studied 150 cognitively unimpaired participants and 100 patients with mild cognitive […]

Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease.

Pereira JB, Janelidze S, Ossenkoppele R, Kvartsberg H, Brinkmalm A, Mattsson-Carlgren N, Stomrud E, Smith R, Zetterberg H, Blennow K, Hansson O. Brain. 2020 Dec 5:awaa395. doi: 10.1093/brain/awaa395. Online ahead of print. Abstract It is currently unclear how amyloid-β and tau deposition are linked to changes in synaptic function and axonal structure over the course […]